Home Market News Micro Cap Stocks Breast Most cancers-Centered Atossa Therapeutics Can Presumably Change Remedy Paradigm: Analyst

Breast Most cancers-Centered Atossa Therapeutics Can Presumably Change Remedy Paradigm: Analyst

0
Breast Most cancers-Centered Atossa Therapeutics Can Presumably Change Remedy Paradigm: Analyst

Cantor Fitzgerald has initiated protection of Atossa Therapeutics Inc ATOS with an Chubby score and a worth goal of $5. 

Analysts Louise Chen, Carvey Leung, Wayne Wu, and Lucas Olson Duffy say that the height gross sales potential of ATOS’ pipeline is underappreciated. 

Cantor notes that the corporate’s lead program (Z)-endoxifen, is a promising new selective estrogen receptor modulator (SERM).

Based on printed research, (Z)-endoxifen is a aggressive inhibitor of ERα and represses ERα transcriptional exercise.

ATOS’ (Z)-endoxifen has been proven to be properly tolerated in Part 1 research and a small Part 2 research of ladies with breast most cancers. The corporate is learning (Z)-endoxifen in three Part 2 research. 

(Z)-endoxifen has the potential to work in all three areas of the Breast Most cancers Paradigm – To mitigate breast most cancers threat, cut back the most cancers cell exercise earlier than surgical procedure, and cut back the danger of recurrent or new breast most cancers after the preliminary remedy.

The analyst expects constructive information readouts to drive upward earnings estimate revisions and ATOS’ inventory larger. 

Cantor notes the market has underappreciated (Z)-endoxifen’s potential throughout prevention settings, neoadjuvant/ Window of Alternative, and adjuvant settings in breast most cancers, in addition to its security profile.

Value Motion: ATOS shares are up 16.60% at $0.87 on the final test Friday.